We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
2017 was an important node in the development of CAR T-cell immunotherapy, where the two cell immunotherapies of Novartis and Gilead were successively approved by FDA.